Prevention strategies for CV health
- Zeljko Reiner, Croatia
- Alexandros Tselepis, Greece
Behaviour change in CVD prevention
Heike Englert, Münster, Germany
Can technology improve adherence to lifestyle?
Gil Blander, Boston, USA
Precision nutrition and CVD management
Jogchum Plat, Maastricht, The Netherlands
EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.
Novel approaches to lipid lowering management
- Alberico L. Catapano, Italy
- Marja-Riita Taskinen, Finland
What do we know so far about bempedoic acid?
Kausik Ray, London, UK
What is the landscape on lipid management today?
Lale Tokgözoglu, Ankara, Turkey
When do we need add on therapies to statin?
Ulrich Laufs, Leipzig, Germany
EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.
Targeting lower LDL-C: When and how?
- Lale Tokgözoglu, Turkey
- David Wood, UK
An update on the results of ODYSSEY outcomes
Gabriel Steg, Paris, France
Are the new EAS/ESC lipids goals reachable in clinical practice?
François Mach, Geneva, Switzerland
Risk stratification in very high risk patients is it of value?
Kausik Ray, London, UK
EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.
The role of TG-rich lipoproteins in atherosclerosis
- Jan Boren, Sweden
- Philippe Moulin, France
Case: Diabetic patient with MI - how to manage?
Dirk Mueller, Köln, Germany
Position of omega 3 in Guidelines (as second choice after statins)
Christie Ballantyne, Houston, USA
TG-rich lipoproteins as a risk factor
Ruth Frikke-Schmidt, Copenhagen, Denmark
The value of omega 3: from biology to clinical practice
Alberto Zambon, Padova, Italy
EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.
Implementing guidelines: a patient-centered approach for daily practice
- Marat Ezhov, Russia
- Paolo Parini, Sweden
Can combination aid adherence? (fixed dose, intolerance)
Michal Vrablik, Prague, Czech Republic
Difficult cases to reach goal: FH
Meral Kayikcioglu, Izmir, Turkey
Difficult cases to reach goal: Recurrent event on statin
Michel Farnier, Dijon, France
Translating science into guidance on the prevention of cardiovascular disease
Guy de Backer, Ghent, Belgium
Why and in whom is combination needed?
Luis Masana, Barcelona, Spain
EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.
New ways to modulate TG metabolic pathways
- Christoph Binder, Austria
- Arnold von Eckardstein, Switzerland
ANGPTL 3 Inhibition: recent clinical trials
Daniel Gaudet, Montreal, Canada
ANGPTL 3 what we have learned from genetics?
Marcello Arca, Rome, Italy
The Angiopoietin-like proteins, controlling lipoprotein metabolism
Sander Kersten, The Netherlands
EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.
Lowering circulating PCSK9 to reduce LDL cholesterol: Current approaches
- Alberico L. Catapano, Italy
- Lale Tokgözoglu, Turkey
Monoclonal antibody approaches targeting circulating PCSK9
Ulf Landmesser, Berlin, Germany
siRNA based approaches targeting hepatic synthesis of PCSK9
Kausik Ray, London, UK
The biology of PCSK9
Bertrand Cariou, Nantes, France
EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.
